Study on the polymorphisms of CYP3A5 and GSTP1 genes in the prediction of short-term efficacy of docetaxel plus thiotepa for patients with metastatic breast cancer
- Author:
Xin-Na ZHOU
1
Author Information
1. Department of Pharmacy Administration and Clinical Pharmacy
- Publication Type:Journal Article
- Keywords:
Breast cancer;
CYP3A5;
Docetaxel;
Drug metabolizing enzyme;
GSTP1;
Polymorphism;
Thiotepa
- From:
Chinese Pharmaceutical Journal
2012;47(2):127-131
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE: To investigate whether the polymorphisms of cytochrome P450 3A5 (CYP3A5) gene and glutathione S-transferase P1 (GSTP1) gene are associated with the short-term efficacy of docetaxel plus thiotepa for Chinese patients with metastatic breast cancer. METHODS: All patients received docetaxel plus thiotepa chemotherapy. CYP3A5 and GSTP1 were genotyped by matrix assisted laser desorption ionization / time of flight (MALDI-TOF). Disease control rate (DCR) was evaluated every two chemotherapy cycles, and was compared between different genotypes. RESULTS: Among 93 enrolled patients, people with CYP3A5 A6986G GG genotype showed a statistically higher DCR than those with AG + GG genotype (77.8% versus 57.4%, P < 0.05), and the DCR of the patients with GSTP1 A313G AG + GG was statistically higher than that of patients with AA (81.6% versus 57.4%, P < 0.05). Combination analysis showed that patients with GSTP1 A313G AG + GG and CYP3A5 A6986G GG had the highest DCR (84.2%, P < 0.05). CONCLUSION: CYP3A5 and GSTP1 polymorphisms are associated with the short-term efficacy of docetaxel plus thiotepa. Higher DCRs were seen in patients carrying GSTP1 A313G AG + GG and / or CYP3A5 A6986G GG genotype, which might be a reference for clinical chemotherapy. Copyright 2012 by the Chinese Pharmaceutical Association.
